This article is more than 5 years old. Information may no longer be current.

FDA approves TonoPach for glaucoma diagnosis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JENKINTOWN, Pa. — A device that combines tonometry and pachymetry in one unit has received U.S. marketing approval, according to the device’s marketer. The TonoPach makes possible “more accurate” diagnosis of glaucoma and ocular hypertension, the company said in a press release.

RetinaPharma Technologies said the Food and Drug Administration granted marketing approval to the company’s TonoPach, calling it “the first device to enable simultaneous determination of IOP and corneal thickness, increasing the accuracy and predictive power of the IOP measurement that is usually taken alone.” Company executives said the TonoPach should be used in a manner identical to existing instruments. The device provides a measurement of corneal thickness at the same spot where it takes the IOP reading, according to the press release.